5 enrolling by invitation. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Enrolling by invitation 5 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria barzolvolimab, Standard of Care - Chronic Spontaneous Urticaria | Phase 3 | Enrolling by invitation | Celldex Therapeutics | 1370 | 2025-11-25 | 2026-10-07 |
| A Long-Term Study of Navenibart in Participants With Hereditary Angioedema navenibart - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Astria Therapeutics, Inc. | 145 | 2025-10-01 | 2026-07-30 |
| Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 170 | 2025-02-01 | 2026-09-22 |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies berotralstat - Hereditary Angioedema, HAE | Phase 3 | Enrolling by invitation | BioCryst Pharmaceuticals | 139 | 2021-07-23 | 2025-12-23 |
Angioedemas, Hereditary (4) · Angioedema (1) · Chronic Urticaria (1) · Hereditary Angioedema Type III (1) · Hereditary Angioedema Types I and II (1)
Hypersensitivity (5) · Hypersensitivity, Immediate (5) · Immune System Diseases (5) · Skin Diseases (5) · Skin Diseases, Vascular (5) · Skin and Connective Tissue Diseases (5) · Cardiovascular Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Hereditary Complement Deficiency Diseases (4) · Immunologic Deficiency Syndromes (4) · Primary Immunodeficiency Diseases (4) · Vascular Diseases (4) · Angioedema (3)
Standard of Care (1) · berotralstat (1)
Pharvaris Netherlands B.V. (2) · Astria Therapeutics, Inc. (1) · BioCryst Pharmaceuticals (1) · Celldex Therapeutics (1)
Canada (5) · France (5) · Germany (5) · Poland (5) · South Africa (5) · Spain (5) · United Kingdom (5) · Bulgaria (4) · Czechia (4) · Italy (4) · South Korea (4) · United States (4) · Argentina (3) · Australia (3) · Brazil (3)
Vesna Grivcheva-Panoska, MD, PhD (1)
2023 (1)